USA flag logo/image

An Official Website of the United States Government

Therapeutic Potential of PARP inhibitor for Acute Pancreatitis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96078
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
DK089821
Solicitation Year:
N/A
Solicitation Topic Code:
NIDDK
Solicitation Number:
N/A
Small Business Information
ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd Uniondale, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Therapeutic Potential of PARP inhibitor for Acute Pancreatitis
Agency: HHS
Contract: 1R43DK089821-01
Award Amount: $219,145.00
 

Abstract:

DESCRIPTION (provided by applicant): Acute Pancreatitis (AP) is a potentially lethal inflammatory disease of the pancreas. Its pathogenesis remains obscure and is involved in a process of acute inflammation and necrosis in the pancreas, with variable invol vement of regional tissues or organ systems that leads to a systemic inflammatory response. AP contributes to thousands of annual hospital admissions and consecutive complications. In the US alone, gt300,000 patients are hospitalized annually with AP leadi ng to 7,200 deaths. In the majority of patients, the condition is mild, but 25% of patients suffer a severe attack, and between 30 and 50%of the patients will die. The most common causes of AP is the presence of gallstones and heavy alcohol (60%-80%) use t hat cause inflammation and necrosis of the pancreas. Other causes include trauma, infections, medications, and tumors of the pancreas. For mild cases, standard therapy and current treatments are non-steroidal anti-inflammatory drugs (NSAID) and corticoster oids, antibiotics, and nutrition supplements. Standard therapy for patients with severe disease includes early invasive monitoring and resuscitation, prophylactic antibiotics, nutrition, and serial CT scanning to identify infection and necrosis. There is n o single effective therapeutic strategy for severe acute pancreatitis. Recently, despite the use of less invasive techniques, complications following debridement of necrotic pancreatic tissue are still common and the mortality rate with severe AP is still high. It also inflicts a heavy economic burden; the direct cost in the US alone is more than 2 billion annually. Hence there is a critical need for effective and affordable non-surgical therapy for AP. Poly (ADP-ribose) polymerase (PARP), a nuclear enzyme , plays an important role in the pathogenesis of AP. Recent studies have shown that oxygen-derived free radicals play a crucial role in the pathogenesis of AP. Oxidative stress caused by free radicals and activation of PARP has been proposed as a common me chanism for pancreatic injury in alcohol, gallstone and ischemic pancreatitis as well as in other experimental models of AP. PARP overactivation, depletes the intracellular concentration of NAD+ and ATP, thus leading to cellular dysfunction and cell death. One of the most exciting areas of research for the treatment of pancreatic injury is to inhibit PARP activation. Using a product discovery engine comprising 3-D molecular modeling, we successfully identified two novel small molecules that inhibit PARP act ivity in vitro and exerts protective effects in in vivo models of AP and toxic injury. Our therapeutic strategy is designed to bring one of the best PARP inhibitor to further study and bring to clinical trials to attenuate patient morbidity and mortality a ssociated with severe AP. PUBLIC HEALTH RELEVANCE: Pancreatitis (AP) is an inflammatory and necrotic disease of the pancreas and severe AP is associated with systemic inflammatory response with high morbidity and mortality. Poly (ADP-ribose) polymer ase (PARP), a nuclear enzyme, plays an important role in the pathogenesis of AP. DNA damage by reactive oxygen/nitrogen free radicals in pancreatic injury and consequent over-activation of PARP promotes pancreatic cellular dysfunction/cell death leading to AP. Current therapeutic methods are insufficient for the treatment of severe AP. One of the most exciting areas of research for the treatment of pancreatic injury is to inhibit PARP activation. Using a 3-D molecular modeling, we successfully identified tw o novel PARP inhibitors. Our therapeutic strategy in the current project is to test our lead PARP inhibitors in two invivo models of AP and identifify one of the best PARP inhibitor to further studies in Phase II and potentially a clinical product.

Principal Investigator:

Latha Paka
5165621278
SPAKA@ANGION.COM

Business Contact:

Dgoldberg M. Itxhak
igoldberg@angion.com
Small Business Information at Submission:

ANGION BIOMEDICA CORPORATION
ANGION BIOMEDICA CORP 1050 Stewart Ave. GARDEN CITY, NY 11530

EIN/Tax ID: 111343007
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No